GLP-1 receptor agonists

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

By MedXY 10/31/2025

This article critically compares the efficacy, safety, and long-term outcomes of tirzepatide, semaglutide, and liraglutide for the treatment of obesity based on recent Cochrane systematic reviews, highlighting differences in weight loss, adverse events, cardiovascular outcomes, and evidence certainty.

Diabetes & Endocrinology news Ophthalmology

Glucagon-Like Peptide-1 Receptor Agonists and Ocular Risks: A Comprehensive Review of Neovascular AMD, Diabetic Retinopathy, and Ischemic Optic Neuropathy in Diabetes

By MedXY 10/29/2025

GLP-1 receptor agonists used in diabetes show a twofold increased risk of neovascular AMD, a modest risk elevation for diabetic retinopathy, and a small but significant increased risk for nonarteritic anterior ischemic optic neuropathy, warranting careful ophthalmic monitoring.

Clinical Updates Neurology news

GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: Emerging Evidence and Clinical Implications

By MedXY 10/27/2025

GLP-1 receptor agonists show promise in idiopathic intracranial hypertension by reducing symptoms, medication use, surgical interventions, and mortality, independent of significant BMI change, highlighting a novel therapeutic approach warranting further prospective evaluation.

Internal Medicine news

Comparative Effectiveness and Costs of Bariatric Surgery Versus GLP-1 Receptor Agonists in Obesity Management

By MedXY 10/27/2025

This article reviews recent evidence comparing weight loss outcomes and healthcare costs of bariatric surgery and GLP-1 receptor agonists, highlighting implications for clinical decision-making in treating class II and III obesity.

Diabetes & Endocrinology news Ophthalmology

Glucagon-Like Peptide-1 Receptor Agonists May Lower the Risk of Nonexudative Age-Related Macular Degeneration in Obese Non-Diabetic Adults

By MedXY 10/26/2025

A large retrospective cohort study reveals that GLP-1 receptor agonists significantly reduce the risk of developing nonexudative age-related macular degeneration in obese individuals without diabetes, with no effect on progression to exudative AMD.

Diabetes & Endocrinology General Surgery news

Patterns and Predictors of GLP-1 Agonist Use After Bariatric Surgery in US Adults

By MedXY 10/10/2025

A large US cohort study reveals that 14% of bariatric surgery patients start GLP-1 receptor agonists postoperatively, with higher use seen among women, sleeve gastrectomy recipients, and those with greater BMI regain.

Clinical Updates Diabetes & Endocrinology Neurology news Specialties

Promising Links Between Diabetes Medications and Alzheimer’s Disease Risk Reduction

By MedXY 09/25/2025

Recent real-world data suggest GLP-1 receptor agonists and SGLT2 inhibitors may lower Alzheimer’s disease risk more effectively than DPP-4 inhibitors, highlighting the need for randomized trials to confirm potential neuroprotective benefits.

Clinical Updates Diabetes & Endocrinology news Specialties

Injectable GLP-1 Use Soars Among US Adults with Diabetes: Trends and Clinical Implications

By MedXY 09/07/2025

Nearly 1 in 4 US adults with diabetes used injectable GLP-1 receptor agonists in 2024, reflecting rising adoption for glycemic control and obesity management with notable demographic disparities.

Clinical Updates news

GLP-1 Receptor Agonists in Obesity: Emerging Evidence for Cancer Risk Modulation

By MedXY 08/31/2025

GLP-1 receptor agonists, used for obesity and type 2 diabetes management, are linked to a 17% lower overall cancer risk, notably hormone-sensitive cancers, but may increase kidney cancer risk. Further research is needed to clarify safety and mechanisms.

Clinical Updates Diabetes & Endocrinology Specialties

Enhancing Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes: Insights from Dapagliflozin and Exenatide Combination Therapy

By MedXY 08/23/2025

Dapagliflozin and exenatide independently improve beta-cell function and insulin sensitivity in type 2 diabetes; their combination markedly enhances these effects, suggesting superior glycemic control potential.

Clinical Updates Diabetes & Endocrinology news Specialties

GLP-1 Receptor Agonists and Dementia Risk in Older Adults With Type 2 Diabetes: Insights From a Target Trial Emulation

By MedXY 07/31/2025

A large-scale emulated trial found no clear overall reduction in dementia risk with GLP-1 receptor agonists versus DPP-4 inhibitors in older adults with type 2 diabetes, though age-specific effects warrant further investigation.